120 related articles for article (PubMed ID: 2148742)
1. Phase II trial of menogaril as initial chemotherapy for metastatic breast cancer.
Kennedy MJ; Donehower RC; Grochow LB; Ettinger DS; Fetting JH; Abeloff MD
Invest New Drugs; 1990 Aug; 8(3):289-94. PubMed ID: 2148742
[TBL] [Abstract][Full Text] [Related]
2. Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.
Eisenhauer EA; Pritchard KI; Perrault DJ; Verma S; Pater JL
Invest New Drugs; 1990 Aug; 8(3):283-7. PubMed ID: 2148741
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of menogaril in patients with advanced cancer.
Brown TD; Donehower RC; Grochow LB; Rice AP; Ettinger DS
J Clin Oncol; 1987 Jan; 5(1):92-9. PubMed ID: 2949065
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
Stewart DJ; Eisenhauer EA; Skillings J; Pritchard KI; Buckman R; VAndenberg T; Verma S; Aitken S; Norris B
Ann Oncol; 1992 Mar; 3(3):201-4. PubMed ID: 1534021
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of intravenous menogaril in patients with advanced breast cancer.
Sessa C; Gundersen S; ten Bokkel Huinink W; Renard J; Cavalli F
J Natl Cancer Inst; 1988 Sep; 80(13):1066-9. PubMed ID: 2970554
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy.
Long HJ; Schaid DJ; Schutt AJ; Ingle JN; Loprinzi CL; Edmonson JH
Am J Clin Oncol; 1988 Oct; 11(5):524-7. PubMed ID: 2972192
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of menogaril in advanced colorectal cancer.
Holdener EE; ten Bokkel Huinink WW; Decoster G; Ludwig C; Renard G; Pinedo HM
Invest New Drugs; 1988 Sep; 6(3):227-30. PubMed ID: 2973448
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).
Stephens RL; Goodman P; Crawford ED; Spicer CF; Lowe BA; Ahmann FR; Chapman R; Natale RB
Invest New Drugs; 1990; 8 Suppl 1():S69-71. PubMed ID: 2143177
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of oral menogaril administered on three consecutive days.
Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Joggi J; Kenis Y
Acta Oncol; 1988; 27(5):517-20. PubMed ID: 2974291
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days.
Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Piccart M; Tueni E; Joggi J; Kenis Y
Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1019-26. PubMed ID: 2970391
[TBL] [Abstract][Full Text] [Related]
12. A phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. A collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic.
Long HJ; Laurie JA; Wieand HS; Edmonson JH; Levitt R; Krook JE; Abu-Ghazaleh S
Cancer; 1991 Aug; 68(4):730-2. PubMed ID: 1830238
[TBL] [Abstract][Full Text] [Related]
13. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group study.
Skillings J; Cripps C; Eisenhauer E; Pater J; Verma S; Walde D
Invest New Drugs; 1991 Feb; 9(1):79-82. PubMed ID: 1827434
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of menogaril (NSC-269148) in colorectal carcinoma. A Southwest Oncology Group study.
Whitehead RP; Earhart RH; Fleming T; Goodman P; Macdonald JS; Pollock T; Ungerleider JS
Invest New Drugs; 1990 Aug; 8(3):295-7. PubMed ID: 2148743
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of menogaril in patients with advanced hypernephroma.
Long HJ; Hauge MD; Therneau TM; Buckner JC; Frytak S; Hahn RG
Invest New Drugs; 1991 Aug; 9(3):261-2. PubMed ID: 1838363
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of intravenous menogaril in advanced ovarian carcinoma. EORTC Early Clinical Trials Group.
Sessa C; Kaye SB; Renard J; ten Bokkel Huinink W; Cavalli F
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):751-2. PubMed ID: 2523809
[No Abstract] [Full Text] [Related]
18. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study.
Ettinger DS; Finkelstein DM; Abeloff MD; Skeel RT; Stott PB; Frontiera MS; Bonomi PD
J Natl Cancer Inst; 1992 Jul; 84(14):1077-84. PubMed ID: 1320131
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of menogaril in patients with metastatic sarcomas and no prior chemotherapy exposure.
Buckner JC; Edmonson JH; Ingle JN; Schaid DJ
Am J Clin Oncol; 1989 Oct; 12(5):384-6. PubMed ID: 2529759
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of oral menogaril administered daily for 14 consecutive days.
Stewart DJ; Aitken SE; Verma S; Maroun JA; Robillard L; Touchie M; Prosser IA; Earhart R
Ann Oncol; 1992 May; 3(5):401-3. PubMed ID: 1535508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]